8-KOther Events

BECTON DICKINSON & CO 8-K Report (May 2, 2003)

Filed May 2, 2003For Securities:BDX

Summary

This Form 8-K filing from Becton, Dickinson and Company (BDX) on May 1, 2003, reports on significant stock option exercises and subsequent sales by key executives. Specifically, Vincent A. Forlenza, President of BD Biosciences, exercised options for 84,428 shares and sold them all. William A. Kozy, President of BD Clinical Laboratory Solutions and Company Operations, exercised options for 50,000 shares and also sold all of them. William A. Tozzi, Vice President and Controller, exercised options for 9,700 shares and sold 8,400 of them. While these executives have reduced their direct shareholdings through these sales, the filing details their continued ownership of a substantial number of shares through direct holdings and participation in the company's Savings Incentive Plan. Investors should note that these transactions are primarily related to the exercise and sale of vested options and do not necessarily reflect a change in the executives' long-term confidence in the company, but rather a liquidation of those specific vested options.

Key Highlights

  • 1Key executives Vincent A. Forlenza and William A. Kozy exercised and sold all shares from their option grants.
  • 2William A. Tozzi exercised options and sold a majority of the shares received.
  • 3The filings are made under Regulation FD, indicating public disclosure of these executive transactions.
  • 4Despite the sales, executives retain significant ownership through direct holdings and savings plans.
  • 5Vincent A. Forlenza's post-transaction ownership: 30,529 shares (25,895 direct, 4,633 in savings plan).
  • 6William A. Kozy's post-transaction ownership: 37,657 shares (32,944 direct, 4,712 in savings plan).
  • 7William A. Tozzi's post-transaction ownership: 8,077 shares (4,149 direct, 3,923 in savings plan).

Frequently Asked Questions

The main purpose of this 8-K filing is to publicly disclose material information regarding the exercise of stock options and subsequent sale of shares by several key executives of Becton, Dickinson and Company, in compliance with Regulation FD.

No, the executives exercised options for a specific number of shares and then sold those acquired shares. They still maintain an ownership interest in a considerable number of shares through direct holdings and their participation in Becton Dickinson's Savings Incentive Plan.

Not necessarily. These transactions involve the exercise and sale of vested stock options, which is a common practice for executives to diversify their holdings or realize gains. The filings show that the executives still hold a significant number of shares, suggesting ongoing commitment to the company.

Vincent A. Forlenza is President of BD Biosciences. William A. Kozy is President of BD Clinical Laboratory Solutions and Company Operations. William A. Tozzi is Vice President and Controller.